866-997-4948(US-Canada Toll Free)

Endometrial Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 533 Pages

Endometrial Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 37, 35, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Endometrial Cancer - Overview 7
Endometrial Cancer - Therapeutics Development 8
Endometrial Cancer - Therapeutics Assessment 21
Endometrial Cancer - Companies Involved in Therapeutics Development 35
Endometrial Cancer - Drug Profiles 63
Endometrial Cancer - Dormant Projects 506
Endometrial Cancer - Discontinued Products 508
Endometrial Cancer - Product Development Milestones 509
Appendix 523

List of Tables
Number of Products under Development for Endometrial Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Endometrial Cancer - Pipeline by AbbVie Inc, H1 2017
Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
Endometrial Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Endometrial Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
Endometrial Cancer - Pipeline by ArQule Inc, H1 2017
Endometrial Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2017
Endometrial Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Bayer AG, H1 2017
Endometrial Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Endometrial Cancer - Pipeline by BioNTech AG, H1 2017
Endometrial Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Endometrial Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Cellceutix Corp, H1 2017
Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
Endometrial Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Endometrial Cancer - Pipeline by Eisai Co Ltd, H1 2017
Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2017
Endometrial Cancer - Pipeline by Endocyte Inc, H1 2017
Endometrial Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Exelixis Inc, H1 2017
Endometrial Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Endometrial Cancer - Pipeline by Galena Biopharma Inc, H1 2017
Endometrial Cancer - Pipeline by GamaMabs Pharma SA, H1 2017
Endometrial Cancer - Pipeline by Genmab A/S, H1 2017
Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Endometrial Cancer - Pipeline by Glycotope GmbH, H1 2017
Endometrial Cancer - Pipeline by Gradalis Inc, H1 2017
Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Endometrial Cancer - Pipeline by Immunocore Ltd, H1 2017
Endometrial Cancer - Pipeline by ImmunoGen Inc, H1 2017
Endometrial Cancer - Pipeline by Immunomedics Inc, H1 2017
Endometrial Cancer - Pipeline by Incyte Corp, H1 2017
Endometrial Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Endometrial Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Endometrial Cancer - Pipeline by MedImmune LLC, H1 2017
Endometrial Cancer - Pipeline by Merck & Co Inc, H1 2017
Endometrial Cancer - Pipeline by Merck KGaA, H1 2017
Endometrial Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Merus NV, H1 2017
Endometrial Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Novartis AG, H1 2017
Endometrial Cancer - Pipeline by Pfizer Inc, H1 2017
Endometrial Cancer - Pipeline by Pharma Mar SA, H1 2017
Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
Endometrial Cancer - Pipeline by Sanofi, H1 2017
Endometrial Cancer - Pipeline by Shenogen PharmaGroup Ltd, H1 2017
Endometrial Cancer - Pipeline by Sigma-Tau SpA, H1 2017
Endometrial Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2017
Endometrial Cancer - Pipeline by Tesaro Inc, H1 2017
Endometrial Cancer - Dormant Projects, H1 2017
Endometrial Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Endometrial Cancer - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Endometrial Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *